SecBot SecBot
Insider Cluster (3 insiders) ·Filed May 15, 2026

KPTI

Karyopharm Therapeutics Inc.
BEARISH
Impact 6/10
Horizonweeks Processed6mo ago
Insider cluster: 2 insiders, $23K total
Actionable Insight ▼ Bearish

The insider sales are too small to be informative on their own, but the cluster's timing with earnings and the massive shelf registration signals that insiders are not buying the dip. The $400M shelf overhang and going-concern warning dominate the narrative. Monitor for any ATM drawdown or further insider selling; the stock is likely to remain under pressure until the capital raise is resolved.

DirectionBearish
Confidencehigh
Horizonweeks

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$7.14
T+0 close · May 15, 2026 · via day close
Latest settled
−71.57%
T+60 · $2.03
Vs SPY
−76.42%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 18 $7.14entry
  2. T+1 · 6mo ago +4.62%α +5.27% · $7.47
  3. T+5 · 6mo ago +25.63%α +24.01% · $8.97
  4. T+20 · 5mo ago +27.45%α +25.87% · $9.10
  5. T+60 · 3mo ago −71.57%α −76.42% · $2.03

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Karyopharm's CEO, CAO, and EVP/CLO sold a total of $23K in open-market shares on May 14, 2026, the same day the company reported Q1 earnings that beat EPS consensus by 29% but included a going-concern warning and a $400M shelf filing. The sales are trivial at 0.01% of market cap and likely liquidity-driven following equity grants, but the cluster's timing with earnings and the massive dilution overhang from the shelf registration creates a bearish context.

Key Financial Metrics

Direction
selling
Total Value
$24.0K
Insiders
3

Key Facts

  • CEO Richard Paulson sold 2,203 shares at $9.50 for $20,929 on May 14, 2026.
  • CAO Kristin Abate sold 53 shares at $9.50 for $504 on May 14, 2026.
  • EVP/CLO Michael Mano sold 266 shares at $9.50 for $2,527 on May 14, 2026.
  • Total open-market sales: $23,959, representing 0.01% of KPTI's $201M market cap.
  • All three insiders also received non-cash equity grants (shares) on May 13, 2026, totaling 5,741 shares at $0.
  • The sales occurred one day after Q1 2026 earnings (revenue $35.1M, net loss -$22.4M, EPS beat consensus by 29%) and 11 days after a $400M shelf registration was filed.
  • The $400M shelf (including a $100M ATM) represents ~200% of market cap; the company has a going-concern warning and cash runway only into late Q3 2026.
  • The insider sales are trivial in dollar terms but cluster with earnings and a dilutive capital raise, per cross-filing actuarial amplifiers.

Financial Impact

Open-market sales of $23,959 (0.01% of market cap) are immaterial in isolation, but the context of a $400M shelf (200% dilution) and going-concern warning is highly material.

dilutioncash runwaymarket cap

Risk Factors

  • Massive dilution from the $400M shelf registration (200% of market cap) if fully utilized.
  • Going-concern warning with cash runway only into late Q3 2026, forcing a dilutive capital raise.
  • Phase 3 SENTRY myelofibrosis trial missed a co-primary endpoint, reducing pipeline optionality.
  • Insider sales, though small, may signal lack of confidence in the near-term outlook.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
85% bullish (13 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 SEC document filed with EDGAR.

DocumentAccession Number
CLUSTER Data (Synthetic)cluster-KPTI-1778875595275

US Market Status

Market Closed · Opens in 8h 44m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 15, 2026